Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. Marcom PK, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2007 Mar;102(1):43-9. doi: 10.1007/s10549-006-9307-8. Epub 2006 Aug 8. Breast Cancer Res Treat. 2007. PMID: 16897431 Clinical Trial.
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.
Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F; Kathleen Cuningham Consortium for Research into Familial Breast Cancer; Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Moorman PG, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2010 Nov;124(2):441-51. doi: 10.1007/s10549-010-0842-y. Epub 2010 Mar 23. Breast Cancer Res Treat. 2010. PMID: 20309627 Free PMC article.
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, Warren R, Eng-Wong J, Cohen P, Smith KL, Creswell K, Novielli A, Slack R. Isaacs C, et al. Breast Cancer Res Treat. 2011 Jan;125(1):137-43. doi: 10.1007/s10549-010-1226-z. Epub 2010 Oct 26. Breast Cancer Res Treat. 2011. PMID: 20976541 Free PMC article. Clinical Trial.
BRCA1/2 mutations and triple negative breast cancers.
Peshkin BN, Alabek ML, Isaacs C. Peshkin BN, et al. Among authors: isaacs c. Breast Dis. 2010;32(1-2):25-33. doi: 10.3233/BD-2010-0306. Breast Dis. 2010. PMID: 21778580 Free PMC article. Review.
510 results